Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsBlue Cross Blue Shield MA mupirocin Coverage Updat…
    Ask Trek AI about this page
    CurrentBlue Cross Blue Shield - MassachusettsPolicy 062

    Mupirocin step therapy and quantity limits

    Customize your policy alerts

    Sign up for Blue Cross Blue Shield - Massachusetts Policy 062 alerts

    Get alerted when Policy 062 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    BCBSMA policy governing step therapy, formulary status, and quantity dosing rules for mupirocin products for commercial members; includes prior authorization and individual exception processes.

    Policy Summary
    PayerBlue Cross Blue Shield - Massachusetts
    PolicyMupirocin step therapy and quantity limits
    Policy CodePolicy 062
    Change TypeNo material change
    Effective Date
    Next Review Date
    Key ActionSubmit prior authorization or step therapy documentation (Massachusetts Standard Form or eForm) and supporting clinical records when prior claims do not demonstrate required prior use.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    AppliesStep therapy
    Policy 621BQuantity limits
    130 days

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Lookback
    CommercialPlan scope
    Not sufficientSample-based requests

    Coverage and Formulary Rules

    Step Therapy / Formulary Criteria

    Coverage and step therapy rules for mupirocin products

    Mupirocin Ointment (generic/Bactroban-style): Covered with no step requirements

    Formulary status: Covered, QCD

    Mupirocin Cream: Requires prior use of ONE step 1 medication OR history of prior use of any step 2 medication within the previous 130 daysprior use within 130 days

    Formulary status: ST, QCD

    Centany AT / Centany (mupirocin ointment): Non-formulary (NFNC) and require prior use of ONE Step 1 and ONE Step 2 medication

    NFNC products require trial of both tiers before coverage

    This policy applies to BCBSMA commercial products with the Blue Cross Blue Shield of Massachusetts formulary, including Managed Care (HMO/POS), PPO/EPO, Indemnity, Medex with Rx plans, and Managed Blue for Seniors. This policy does not apply to Medicare Advantage plans.

    Requests based solely on the use of medication samples will not meet the coverage criteria for an individual exception and therefore will not be approved. Providers must submit additional clinical information demonstrating medical necessity for review when seeking coverage outside the criteria.

    Lookback and Coding Notes

    Prior use lookback — 130 days
    Prior use lookback window130 days
    Source for lookback methodPrescription claim records used to support prior use within previous 130 days; provider documentation required when claims unavailable
    ApplicationApplies to step therapy determination for mupirocin cream and step 2 agents per policy rules

    What Providers Must Do

    Prior Authorization

    Prior Authorization and Submission

    Certain mupirocin products require prior authorization or step therapy. Providers may submit the Massachusetts Standard Form for Medication Prior Authorization Requests (eForm) or Form #434 by print and fax. For assistance contact Pharmacy Operations: Phone: 1-800-366-7778 • Fax: 1-800-583-6289.

    • Massachusetts Standard Form for Medication Prior Authorization Requests (eForm) or Form #434
    • Phone: 1-800-366-7778 • Fax: 1-800-583-6289
    Step Therapy

    Step Therapy Requirements

    Mupirocin ointment (including branded and generic ointment formulations) is covered without step therapy requirements. Mupirocin cream is subject to step therapy: prior use of ONE Step 1 medication or documentation of prior use of any Step 2 medication within the previous 130 days is required. Specific non-formulary ointment products (e.g., Centany AT, Centany) may require prior use of one Step 1 and one Step 2 agent.

    • Mupirocin ointment = Covered, no requirements

    Policy Background

    This policy addresses formulary placement, step therapy, and quantity-dosing rules for topical mupirocin formulations used to treat localized skin infections. Mupirocin ointment is formulary-preferred and is covered with no step requirements; formulary quantity limits are managed per the referenced Quality Care Dosing guidelines (Medical Policy #621B). Mupirocin cream is subject to step therapy and requires prior use of either one Step 1 medication or prior use of any Step 2 medication within the previous 130 days. Branded ointments (Centany / Centany AT) are designated non-formulary (NFNC) and require documented trials of one Step 1 and one Step 2 medication before consideration for coverage. Prior use should be demonstrated via prescription claims when available; if claim data are unavailable, provider documentation (for example, chart notes or medication records) may be accepted to establish prior use.

    Key Terms

    QCD - Quality Care Dosing; ST - Step Therapy; NFNC - Non-formulary
    QCDQuality Care Dosing (quantity limits policy #621B)
    STStep Therapy — requirements as specified per product (e.g., mupirocin cream requires prior use of one step 1 medication or prior use of any step 2 medication within previous 130 days)
    NFNCNon-formulary — products (e.g., Centany, Centany AT) require trials of required step 1 and step 2 agents before coverage; may incur higher member cost share if exception approved

    Initial Therapy and Preferred Agents

    Initial therapy

    Formulary-preferred initial agents and lookback requirements

    Preferred ointment initiation: Mupirocin ointment is formulary preferred and covered with no step requirements

    Use quantity limits per Policy #621B if applicable

    Step Therapy Operational Details

    RequirementEvidence of Prior Use
    Prior use requirement for step therapy
    Prior use must be demonstrated via prescription claims or, when claims are unavailable, provider documentation (e.g., chart notes, medication history).

    Quantity and Dosing Limits

    Mupirocin products — subject to Quality Care Dosing limits
    Quantity limits statusMupirocin products are subject to Quality Care Dosing limits (Policy #621B)
    ScopeApplies to all mupirocin formulations listed (ointment, cream, branded ointments) as referenced in step therapy tables
    EnforcementQuantity limits applied per course as defined under QCD policy; see Policy #621B for specific limits
    Policy Summary
    PayerBlue Cross Blue Shield - Massachusetts
    PolicyMupirocin step therapy and quantity limits
    Policy CodePolicy 062
    Change TypeNo material change
    Effective Date
    Next Review Date
    Key ActionSubmit prior authorization or step therapy documentation (Massachusetts Standard Form or eForm) and supporting clinical records when prior claims do not demonstrate required prior use.
    SourceLink
    On This Page
    Coverage and Formulary RulesLookback and Coding NotesWhat Providers Must DoPolicy BackgroundKey TermsInitial Therapy and Preferred AgentsStep Therapy Operational DetailsQuantity and Dosing Limits
  1. Mupirocin cream = Step Therapy (requires prior use of ONE Step 1 medication OR prior use of any Step 2 medication within previous 130 days)
  2. Centany / Centany AT (non-formulary ointments) = Requires prior use of ONE Step 1 and ONE Step 2
  3. Documentation Required

    Required Documentation

    When prescription claim history does not establish prior use within the required 130-day window or does not document trial and failure of formulary alternatives, the provider must submit supporting documentation. Acceptable documentation includes chart notes, lab results, or other clinical information showing trials, dates, doses, and reasons for discontinuation or failure of prior therapies.

    • If prescription claim data unavailable or insufficient, submit chart notes, lab results, or other clinical documentation
    • Include medication names, strengths, dates, duration, and reason for failure or contraindication
    Denial Risk

    Samples and Exception Requests

    Requests based solely on samples will not meet coverage criteria for an exception. Lack of supporting documentation or inability to demonstrate required prior use/trial and failure of formulary alternatives may result in denial. For atypical patients, submit an individual consideration request with comprehensive supporting clinical information.

    • Sample-only requests are not sufficient for exception requests
    • Provide full clinical rationale and documentation for individual consideration requests